Literature DB >> 35478150

The Effect of Convalescent Plasma in Patients With Covid-19 in Intensive Care Unit.

Alina Bereanu1,2, Ovidiu Crisan3, Anne-Marie Constantin4, Simona Cainap4, Calin Cainap4, Raluca Dragulescu2, Rares Bereanu1, Bogdan Vintila1, Corina Roman1,2, Mihai Sava1,2.   

Abstract

BACKGROUND/AIM: Convalescent plasma collected from COVID-19 survivors contains antibodies against receptor binding domains with potent antiviral activity. The use of this therapy for COVID-19 is still under investigation, as the pathophysiological and immunological mechanisms responsible for the evolution of the disease have not been fully identified. PATIENTS AND METHODS: In this retrospective observational study, we included all patients with a confirmed SARS-Cov-2 infection based on positive RT-PCR testing, who received convalescent plasma treatment in addition to standard therapy, between 17.05.2020 and 27.11.2020, following hospitalization in the Anaesthesia and Intensive Care Unit of the Sibiu County Emergency Clinical Hospital, Romania.
RESULTS: Convalescent plasma therapy of patients with SARS-Cov-2 infection and severe forms of the disease (requiring only high-flow oxygen therapy or non-invasive ventilation) significantly improved inflammatory markers (CRP, fibrinogen) and ventilatory parameters (SaO2, paO2, paO2/FiO2) reducing the need of supplemental oxygen delivery (p<0.05). Other factors that had a significant influence on the outcome were age and comorbidity.
CONCLUSION: Inflammatory markers and ventilatory parameters were significantly improved and the need of supplemental oxygen delivery was reduced in COVID-19 patients treated with convalescent plasma.
Copyright © 2022, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Covid-19; SARS-Cov-2; convalescent plasma; hyperimmune plasma

Mesh:

Substances:

Year:  2022        PMID: 35478150      PMCID: PMC9087082          DOI: 10.21873/invivo.12836

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.406


  27 in total

1.  Early safety indicators of COVID-19 convalescent plasma in 5,000 patients.

Authors:  Michael J Joyner; R Scott Wright; DeLisa Fairweather; Jonathon W Senefeld; Katelyn A Bruno; Stephen A Klassen; Rickey E Carter; Allan M Klompas; Chad C Wiggins; John Ra Shepherd; Robert F Rea; Emily R Whelan; Andrew J Clayburn; Matthew R Spiegel; Patrick W Johnson; Elizabeth R Lesser; Sarah E Baker; Kathryn F Larson; Juan G Ripoll; Kylie J Andersen; David O Hodge; Katie L Kunze; Matthew R Buras; Matthew Np Vogt; Vitaly Herasevich; Joshua J Dennis; Riley J Regimbal; Philippe R Bauer; Janis E Blair; Camille M van Buskirk; Jeffrey L Winters; James R Stubbs; Nigel S Paneth; Nicole C Verdun; Peter Marks; Arturo Casadevall
Journal:  J Clin Invest       Date:  2020-06-11       Impact factor: 14.808

2.  Outcomes from intensive care in patients with COVID-19: a systematic review and meta-analysis of observational studies.

Authors:  R A Armstrong; A D Kane; T M Cook
Journal:  Anaesthesia       Date:  2020-07-15       Impact factor: 6.955

3.  COVID-19 and the Path to Immunity.

Authors:  David S Stephens; M Juliana McElrath
Journal:  JAMA       Date:  2020-10-06       Impact factor: 56.272

4.  SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19.

Authors:  Julian Braun; Lucie Loyal; Marco Frentsch; Daniel Wendisch; Philipp Georg; Florian Kurth; Stefan Hippenstiel; Manuela Dingeldey; Beate Kruse; Florent Fauchere; Emre Baysal; Maike Mangold; Larissa Henze; Roland Lauster; Marcus A Mall; Kirsten Beyer; Jobst Röhmel; Sebastian Voigt; Jürgen Schmitz; Stefan Miltenyi; Ilja Demuth; Marcel A Müller; Andreas Hocke; Martin Witzenrath; Norbert Suttorp; Florian Kern; Ulf Reimer; Holger Wenschuh; Christian Drosten; Victor M Corman; Claudia Giesecke-Thiel; Leif Erik Sander; Andreas Thiel
Journal:  Nature       Date:  2020-07-29       Impact factor: 49.962

5.  Convalescent plasma anti-SARS-CoV-2 spike protein ectodomain and receptor-binding domain IgG correlate with virus neutralization.

Authors:  Eric Salazar; Suresh V Kuchipudi; Paul A Christensen; Todd Eagar; Xin Yi; Picheng Zhao; Zhicheng Jin; S Wesley Long; Randall J Olsen; Jian Chen; Brian Castillo; Christopher Leveque; Dalton Towers; Jason Lavinder; Jimmy Gollihar; Jose Cardona; Gregory Ippolito; Ruth Nissly; Ian Bird; Denver Greenawalt; Randall M Rossi; Abhinay Gontu; Sreenidhi Srinivasan; Indira Poojary; Isabella M Cattadori; Peter J Hudson; Nicole M Josleyn; Laura Prugar; Kathleen Huie; Andrew Herbert; David W Bernard; John M Dye; Vivek Kapur; James M Musser
Journal:  J Clin Invest       Date:  2020-12-01       Impact factor: 14.808

Review 6.  Convalescent plasma in Covid-19: Possible mechanisms of action.

Authors:  Manuel Rojas; Yhojan Rodríguez; Diana M Monsalve; Yeny Acosta-Ampudia; Bernardo Camacho; Juan Esteban Gallo; Adriana Rojas-Villarraga; Carolina Ramírez-Santana; Juan C Díaz-Coronado; Rubén Manrique; Ruben D Mantilla; Yehuda Shoenfeld; Juan-Manuel Anaya
Journal:  Autoimmun Rev       Date:  2020-05-05       Impact factor: 9.754

7.  Use of convalescent plasma therapy in SARS patients in Hong Kong.

Authors:  Y Cheng; R Wong; Y O Y Soo; W S Wong; C K Lee; M H L Ng; P Chan; K C Wong; C B Leung; G Cheng
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-01       Impact factor: 3.267

8.  Treatment With Convalescent Plasma for Critically Ill Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection.

Authors:  Bin Zhang; Shuyi Liu; Tan Tan; Wenhui Huang; Yuhao Dong; Luyan Chen; Qiuying Chen; Lu Zhang; Qingyang Zhong; Xiaoping Zhang; Yujian Zou; Shuixing Zhang
Journal:  Chest       Date:  2020-03-31       Impact factor: 9.410

9.  Autoantibodies against type I IFNs in patients with life-threatening COVID-19.

Authors:  Paul Bastard; Lindsey B Rosen; Qian Zhang; Eleftherios Michailidis; Hans-Heinrich Hoffmann; Yu Zhang; Karim Dorgham; Quentin Philippot; Jérémie Rosain; Vivien Béziat; Steven M Holland; Guy Gorochov; Emmanuelle Jouanguy; Charles M Rice; Aurélie Cobat; Luigi D Notarangelo; Laurent Abel; Helen C Su; Jean-Laurent Casanova; Jérémy Manry; Elana Shaw; Liis Haljasmägi; Pärt Peterson; Lazaro Lorenzo; Lucy Bizien; Sophie Trouillet-Assant; Kerry Dobbs; Adriana Almeida de Jesus; Alexandre Belot; Anne Kallaste; Emilie Catherinot; Yacine Tandjaoui-Lambiotte; Jeremie Le Pen; Gaspard Kerner; Benedetta Bigio; Yoann Seeleuthner; Rui Yang; Alexandre Bolze; András N Spaan; Ottavia M Delmonte; Michael S Abers; Alessandro Aiuti; Giorgio Casari; Vito Lampasona; Lorenzo Piemonti; Fabio Ciceri; Kaya Bilguvar; Richard P Lifton; Marc Vasse; David M Smadja; Mélanie Migaud; Jérome Hadjadj; Benjamin Terrier; Darragh Duffy; Lluis Quintana-Murci; Diederik van de Beek; Lucie Roussel; Donald C Vinh; Stuart G Tangye; Filomeen Haerynck; David Dalmau; Javier Martinez-Picado; Petter Brodin; Michel C Nussenzweig; Stéphanie Boisson-Dupuis; Carlos Rodríguez-Gallego; Guillaume Vogt; Trine H Mogensen; Andrew J Oler; Jingwen Gu; Peter D Burbelo; Jeffrey I Cohen; Andrea Biondi; Laura Rachele Bettini; Mariella D'Angio; Paolo Bonfanti; Patrick Rossignol; Julien Mayaux; Frédéric Rieux-Laucat; Eystein S Husebye; Francesca Fusco; Matilde Valeria Ursini; Luisa Imberti; Alessandra Sottini; Simone Paghera; Eugenia Quiros-Roldan; Camillo Rossi; Riccardo Castagnoli; Daniela Montagna; Amelia Licari; Gian Luigi Marseglia; Xavier Duval; Jade Ghosn; John S Tsang; Raphaela Goldbach-Mansky; Kai Kisand; Michail S Lionakis; Anne Puel; Shen-Ying Zhang
Journal:  Science       Date:  2020-09-24       Impact factor: 63.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.